secwatch / observer
8-K filed June 26, 2023, 7:59 PM ET ticker OABI CIK 0001846253
other confidence high sentiment neutral materiality 0.10

OmniAb stockholders elect two Class I directors and ratify auditor at 2023 annual meeting

OmniAb, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OmniAb, Inc. shareholders approved The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-23 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-23
Exact text from the filing
Proposal 2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 87,761,330 224,020 25,982 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OmniAb, Inc. shareholders approved The election of two directors to serve as Class I directors for a three-year term to expire at the 2026 Annual Meeting of Stockholders. at the 2023-06-23 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-23
Exact text from the filing
Proposal 1. The election of two directors to serve as Class I directors for a three-year term to expire at the 2026 Annual Meeting of Stockholders. The following two Class I directors were elected by the votes indicated: For Against Withheld Broker Non-Votes Matthew W. Foehr 73,222,386 665,930 419,424 13,703,592 Jennifer Cochran, Ph.D. 69,340,824 4,553,603 413,313 13,703,592
View on SEC.gov

Browse all shareholder votes →

OmniAb, Inc. filing history →

Source: SEC EDGAR
accession 0001846253-23-000082
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.